Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 6/20 | 1.00 |
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 4/20 | 1.00 |
| ▸ | RORA | P35398 | 3/20 | 1.00 |
| ▸ | OSBP | P22059 | 4/20 | 0.80 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392982 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL19555712 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL281943 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL2525207 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL2530438 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL23810015 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL21617323 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL22959572 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL22959500 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL2530829 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522350-B1 | Use of the active ingredient combination of a 1-diethylaminoethyl-3-chinoxalin-2-on derivative and an oxysterol for breaking resistance in the treatment of cancer and strengthening the immune system against cancer, bacterial and viral diseases, autoimmune diseases, increased stress and environmental influences | IMMUNOPHARM AG (LI) | 2013-07-31 | — | — | EP | disclosed |
| EP-1742636-B1 | Preparation for the treatment cancer | IMMUNOPHARM AG (LI) | 2013-04-10 | — | — | EP | disclosed |
| EP-2522350-A1 | Use of the active ingredient combination of a 1-diethylaminoethyl-3-chinoxalin-2-on derivative and an oxysterol for breaking resistance in the treatment of cancer and strengthening the immune system against cancer, bacterial and viral diseases, autoimmune diseases, increased stress and environmental influences | Immunopharm AG (LI) | 2012-11-14 | — | — | EP | disclosed |
| US-20080200424-A1 | Preparation for Treating Cancer | IMMUNOPHARM AG (LI) | 2008-08-21 | — | — | US | disclosed |
| US-20080200424-A1 | Preparation for Treating Cancer | IMMUNOPHARM AG (LI) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200424-A1 | Preparation for Treating Cancer | CBS, SCLY, GPX1 | GPR183 1832/4885NPC1L1 210/4885RORC 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.